Oisin Biotechnologies's guest appearances

Oisin Biotechnologies

TomorrowScale Podcast

The Longevity Biotech Show

George Church

Lee Cronin

Kristen Fortney

Jim Mellon

Nir Barzilai

Chang Liu

John Krakauer

Daniel Ives

Collin Ewald

Tierra Biosciences

Jay Olshansky

Frank Lichtenberg

Jonathan Gorard

Cambrian Biopharma

Marinna Madrid

OwlTail

Matthew Scholz is the co-founder of Oisin Biotechnologies, a gene therapy platform company that is targeting aging by killing senescent cells. We discuss the technology behind Oisin, Matt's journey from computer science to biotech, and practical advice and wisdom he gained from building biotech startups.

Matthew Scholz is the co-founder of Oisin Biotechnologies, a gene therapy platform company that is targeting aging by killing senescent cells. We discuss the technology behind Oisin, Matt's journey from computer science to biotech, and practical advice and wisdom he gained from building biotech startups.

#012: Matthew Scholz (Oisin Biotechnologies) - May 6th, 2021

Drugs are getting smarter. A new wave of companies, including those founded by our guest, Matthew Scholz of Oisin Biotechnologies and OncoSenX, ride on recent advances in drug and gene delivery that are enabling what could be considered intelligent therapeutics. That is, they are able to both identify target cells (not visibly, but genetically) and then selectively destroy those cancerous or senescent cells. Novel medicines that include a diagnostic targeting system right within them, to potentially treat everything from cancer to aging. This is the TomorrowScale podcast. Oisin Biotechnologies: https://www.oisinbio.com/ OncoSenX: https://www.oncosenx.com/ Follow Us on Twitter: https://twitter.com/TomorrowScale The TomorrowScale Podcast was created by Justin Briggs to showcase scientists and entrepreneurs who are building the future, and to hear their stories from the benches and in the trenches of research &amp; development. The views expressed by the host and guests are their own, and the content of this show should not be considered legal, tax, or investing advice. Thank you to our guests for sharing their time and knowledge with us. Thanks for listening. Please science responsibly.   ---   Support this podcast: https://anchor.fm/tomorrowscale/support

Drugs are getting smarter. A new wave of companies, including those founded by our guest, Matthew Scholz of Oisin Biotechnologies and OncoSenX, ride on recent advances in drug and gene delivery that are enabling what could be considered intelligent therapeutics. That is, they are able to both identify target cells (not visibly, but genetically) and then selectively destroy those cancerous or senescent cells. Novel medicines that include a diagnostic targeting system right within them, to potentially treat everything from cancer to aging. This is the TomorrowScale podcast. Oisin Biotechnologies: <a href="https://www.oisinbio.com/" rel="nofollow" target="_blank">https://www.oisinbio.com/</a> OncoSenX: <a href="https://www.oncosenx.com/" rel="nofollow" target="_blank">https://www.oncosenx.com/</a> Follow Us on Twitter: <a href="https://twitter.com/TomorrowScale" rel="nofollow" target="_blank">https://twitter.com/TomorrowScale</a> The TomorrowScale Podcast was created by Justin Briggs to showcase scientists and entrepreneurs who are building the future, and to hear their stories from the benches and in the trenches of research &amp; development. The views expressed by the host and guests are their own, and the content of this show should not be considered legal, tax, or investing advice. Thank you to our guests for sharing their time and knowledge with us. Thanks for listening. Please science responsibly. --- Support this podcast: <a href="https://anchor.fm/tomorrowscale/support" rel="payment nofollow" target="_blank">https://anchor.fm/tomorrowscale/support</a>

Information Therapeutics - Oisin Biotechnologies & OncoSenX